OXITRAN
Dead / Cancelled — Cancelled — Section 8 (as of 26 Jan 2024)
What this means for you
This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 87093137
- Registration number
- 5239739
- Mark type
- Stylized text
- Filed
- 05 Jul 2016
- Published for opposition
- 07 Mar 2017
- Registered
- 11 Jul 2017
- Attorney of record
- Maria A. Scungio
Goods and services
- Class 001 — Chemicals: Active chemical ingredients for use in the manufacture of small molecule pharmaceuticals for treating neuromuscular and ophthalmological diseases; reagents for scientific and medical research for use in the research of small molecule pharmaceuticals and research of the treatment of neuromuscular and ophthalmological diseases; all of the foregoing excluding cleaning agents for use in laboratories and industries
- Class 005 — Pharmaceuticals: Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of neuromuscular and ophthalmological diseases; Pharmaceutical preparations for the treatment of central nervous system-related conditions, neurological and muscular diseases, neuro-muscular diseases, muscular dystrophies, ataxias, amyotrophia, atrophy, ophthalmological diseases, muscle wasting, cardiomyopathies, optic nerve degradation, neurological indications, memory loss, Lou Gehrig's disease, Parkinson's disease, Huntington's disease, spinal muscular atrophies, polyneuropathies, fibromyalgia, mononeuropathies, neuromuscular junction disorders, myotonia and myopathies; reagents for medical use in connection with the aforementioned diseases
- Class 042 — Scientific and technological services: Medical research; scientific research; medical and scientific research, namely, conducting clinical trials for others; computer programming for others for medical and science research purposes; scientific research for testing cell cultures and developing cellular test systems for evaluating new drugs and antibodies; developing test systems for detecting pharmacologically active compounds; genetic animal model testing and scientific research for neuro-muscular and ophthalmological diseases for research purposes
Owner
- Santhera Pharmaceuticals (Schweiz) AG, Pratteln, CH
- Santhera Pharmaceuticals (Schweiz) AG, Liestal, CH
- Santhera Pharmaceuticals (Schweiz) AG, Liestal, CH
Prosecution history
- 26 Jan 2024 — CANCELLED SEC. 8 (6-YR)
- 11 Jul 2022 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 20 Jun 2018 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 20 Jun 2018 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 11 Jul 2017 — REGISTERED-PRINCIPAL REGISTER
- 02 Jun 2017 — 1(B) BASIS DELETED; PROCEED TO REGISTRATION
- 11 May 2017 — NOTICE OF ALLOWANCE CANCELLED
- 02 Jun 2017 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 11 May 2017 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 02 May 2017 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 07 Mar 2017 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 07 Mar 2017 — PUBLISHED FOR OPPOSITION
- 15 Feb 2017 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 31 Jan 2017 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 25 Jan 2017 — APPROVED FOR PUB - PRINCIPAL REGISTER